Stocks Health care TNGX
NASDAQ · Health careTango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. brought in $53.8M of revenue over the twelve months to June 30, 2026, up 121.5% from a year earlier. It posted a net loss of $123.7M. In fiscal 2025 capital spending exceeded operating cash flow by $139.9M. At June 30, 2026 it held $345.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Tango Therapeutics, Inc. does
Tango Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TNGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $62.4M | -$101.6M | -$0.87 | -$139.9M |
| 2024 | $42.1M | -$130.3M | -$1.19 | -$132.3M |
| 2023 | $36.5M | -$101.7M | -$1.08 | -$119.5M |
| 2022 | $24.9M | -$108.2M | -$1.23 | -$116.8M |
| 2021 | $37M | -$58.2M | -$0.94 | -$61.4M |
| 2020 | $7.7M | -$52M | -$1.63 | $69M |
Latest SEC filings
What Tango Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Other event 8-K
- August 11, 2026
- August 11, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
Questions about TNGX
What does Tango Therapeutics, Inc. do?
Tango Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TNGX.
Is Tango Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $123.7M on revenue of $53.8M.
How much revenue does Tango Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Tango Therapeutics, Inc. reported revenue of $53.8M. That is 121.5% more than a year earlier.
When did Tango Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 24, 2026.
Similar companies
Follow TNGX
Get an email when Tango Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow TNGX: get an email when it filesWhere the numbers come from
Financial figures are the values Tango Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.